Gene therapy of severe combined immunodeficiencies

@article{Fischer2002GeneTO,
  title={Gene therapy of severe combined immunodeficiencies},
  author={Alain Fischer and Salima Hacein-Bey and Marina Cavazzana‐Calvo},
  journal={Nature Reviews Immunology},
  year={2002},
  volume={2},
  pages={615-621}
}
The concept that the outcome of a devastating disease can be modified by inserting a transgene into abnormal cells is appealing. However, the gene-transfer technologies that are available at present have limited the success of gene therapy so far. Nevertheless, severe combined immunodeficiencies are a useful model, because gene transfer can confer a selective advantage to transduced cells. In this way, a proof of concept for gene therapy has been provided. 
Gene therapy for immunodeficiency diseases.
TLDR
Primary immunodeficiency diseases represent good targets for hematopoietic stem cell-targeted gene therapy and new advances in the technology of gene transfer should further promote gene therapy as a safe and effective therapeutic strategy of immunodficiency diseases.
Gene therapy for severe combined immune deficiency.
[Gene therapy of SCID-X1].
TLDR
Activation of cellular proto-oncogenes by accidental integration of the gene vector has been identified as the underlying mechanism and improved vector technology in combination with other protocol modifications may reduce the risk of this side effect.
The evolution of gene therapy in X-linked severe combined immunodeficiency.
  • Tonya S. Rans, Ronald W. England
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2009
Hematopoietic stem cell-based gene therapy against HIV infection: promises and caveats.
TLDR
The extent to which changes to T-cell homeostasis hamper a gene therapy approach, or can be reversed upon HAART, will determine the feasibility of future gene therapy against AIDS.
Immune deficiencies due to defects in cytokine signaling
TLDR
The identification of the genetic defects in humans with SCID provides the basis for future therapies for these patients and insight into the underlying signaling defects in inherited immunodeficiencies is provided.
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease.
TLDR
The CD20 transgene did not alter the functionality of T lymphocytes with respect to allogeneic recognition and cytotoxic response, anti-Epstein-Barr virus cytot toxic response, antigenic response to tetanus toxoid antigen, interleukin 2 (IL-2), IL-4, and interferon gamma production.
T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy
TLDR
HIV-based vectors are emerging as good alternative candidates over the most widely used oncoretroviral vectors due to their peculiar molecular features that fit the ideal conditions for donor T cell in vitro manipulation.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency.
TLDR
Retroviral vector gene transfer is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
TLDR
Ex vivo gene therapy with gamma(c) can safely correct the immune deficiency of patients with X-linked severe combined immunodeficiency and allow patients to have a normal life.
T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years
TLDR
It is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease.
Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning
TLDR
Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions, and lower toxic metabolites, indicating the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
TLDR
A gene therapy trial for SCID-X1 was initiated, based on the use of complementary DNA containing a defective gammac Moloney retrovirus-derived vector and ex vivo infection of CD34+ cells, which provided full correction of disease phenotype and clinical benefit.
Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells
TLDR
Investigation of the control of transgene expression and prevention of vector silencing will become increasingly important for the successful establishment of effective transduction protocols that hinges on retrovirus biology as well as stem cell and transplantation biology.
Restoration of lymphocyte function in Janus Kinase 3-deficient mice by retroviral-mediated gene transfer
TLDR
Results show that gene replacement is a feasible treatment strategy for this disease and that naturally occurring in vivo selection of corrected cells is an important advantage of this approach.
Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach.
TLDR
Transfer of the human gamma(c) gene to repopulating hematopoietic stem cells using an ecotropic retrovirus resulted in an increase in T cells, B cells, natural killer cells, and intestinal intraepithelial lymphocytes, as well as normalization of the CD4:CD8 T-cell ratio and of serum Ig levels.
Retroviral-mediated gene correction for X-linked severe combined immunodeficiency.
X-linked severe combined immunodeficiency (XSCID) is a lethal disease caused by a defect in the gene encoding the common gamma chain (gamma-c) of the receptor for interleukin-2 (IL-2), IL-4, IL-7,
...
1
2
3
4
5
...